Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab

Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.

(2017) Y. Y. Janjigian et al.   JOURNAL OF CLINICAL ONCOLOGY

Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells

(2011) Gang Chen et al.   BIOLOGICAL PROCEDURES ONLINE

Current progress of siRNA/shRNA therapeutics in clinical trials

(2011) John C. Burnett et al.   Biotechnology Journal

New therapeutic avenues in lung cancer based on disturbances in PI3K and RAS pathways

(2011) R. Rosell   EUROPEAN JOURNAL OF CANCER

Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

(2011) N. Sunaga et al.   MOLECULAR CANCER THERAPEUTICS

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

(2010) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of Quantitative Molecular Clinical End Points for siRNA Clinical Trials

(2010) Robyn P. Hickerson et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase-Targeted Agents in Non-Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor

(2010) K. Takezawa et al.   MOLECULAR CANCER THERAPEUTICS

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

(2010) Mark E. Davis et al.   NATURE

Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase–quantitative polymerase chain reaction

(2009) Gang Chen et al.   ANALYTICAL BIOCHEMISTRY

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study

(2009) J. Tabernero et al.   ANNALS OF ONCOLOGY

Retracted: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines

(2009) Shirish M. Gadgeel et al.   CANCER

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

(2009) Anurag Singh et al.   CANCER CELL

Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors

(2009) Yun Jung Choi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

(2009) M. L. Sos et al.   CANCER RESEARCH

The Cell Line Secretome, a Suitable Tool for Investigating Proteins Releasedin Vivoby Tumors: Application to the Study of p53-Modulated Proteins Secreted in Lung Cancer Cells

(2009) Jérôme Chenau et al.   JOURNAL OF PROTEOME RESEARCH

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations

(2009) I. Y.-S. Tam et al.   MOLECULAR CANCER THERAPEUTICS

Amphiregulin Promotes BAX Inhibition and Resistance to Gefitinib in Non-small-cell Lung Cancers

(2009) Benoît Busser et al.   MOLECULAR THERAPY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer

(2009) Songwen ZHOU et al.   RESPIROLOGY

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer

(2008) Z Tang et al.   BRITISH JOURNAL OF CANCER

A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy

(2008) E. Felip et al.   CLINICAL CANCER RESEARCH

Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023

(2008) Karen Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients with Refractory Non-small Cell Lung Cancer (NSCLC): A Phase I Study

(2008) Suresh Ramalingam et al.   Journal of Thoracic Oncology

Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells

(2008) E. Giovannetti et al.   MOLECULAR PHARMACOLOGY

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE

siRNA Targeting against EGFR, a Promising Candidate for a Novel Therapeutic Application to Lung Adenocarcinoma

(2008) Sumitaka Yamanaka et al.   PATHOBIOLOGY

Modeling oncogene addiction using RNA interference

(2008) S. M. Rothenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA